Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 63203
1. Yao Y, Jiang CS, Sun N, Li WQ, Niu Y, Han HQ, Miao ZH, Zhao XX, Zhao J, Li J: Tamaractam, a New Bioactive Lactam from Tamarix ramosissima, Induces Apoptosis in Rheumatoid Arthritis Fibroblast-Like Synoviocytes. Molecules; 2017 Jan 10;22(1)
MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tamaractam, a New Bioactive Lactam from Tamarix ramosissima, Induces Apoptosis in Rheumatoid Arthritis Fibroblast-Like Synoviocytes.
  • Chemical investigation of <i>Tamarix ramosissima</i> Ledeb, a traditional herbal medicine used for rheumatoid arthritis (RA) treatment in northwest China, led to the discovery of a new phenolic aromatic rings substituted lactam, tamaractam (<b>1</b>), together with the previously reported compounds <i>cis</i>-<i>N</i>-feruloyl-3-<i>O</i>-methyldopamine (<b>2</b>) and <i>trans</i>-<i>N</i>-feruloyl-3-<i>O</i>-methyldopamine (<b>3</b>).
  • [MeSH-major] Apoptosis / drug effects. Arthritis, Rheumatoid / drug therapy. Deoxyepinephrine / chemistry. Lactams / chemistry

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28075411.001).
  • [ISSN] 1420-3049
  • [Journal-full-title] Molecules (Basel, Switzerland)
  • [ISO-abbreviation] Molecules
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Lactams; R7339QLN1C / Deoxyepinephrine
  • [Keywords] NOTNLM ; Tamarix ramosissima (major topic) / apoptosis (major topic) / fibroblast-like synoviocytes (major topic) / growth inhibitory activity (major topic) / rheumatoid arthritis (major topic) / tamaractam (major topic)
  •  go-up   go-down


2. Viswanath A, Khanduja V: Can hip arthroscopy in the presence of arthritis delay the need for hip arthroplasty? J Hip Preserv Surg; 2017 Jan;4(1):3-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can hip arthroscopy in the presence of arthritis delay the need for hip arthroplasty?
  • Hip arthroscopy for joint preservation surgery has grown immensely over the last two decades.
  • There is now an increasing trend to try and expand the role of hip arthroscopy to include patients of an older age or perhaps even with signs of arthritis, instead of the established patient group of young adults with mechanical symptoms or serious athletes.
  • Once arthritis is apparent, the arthroscopic procedures needed to try and limit progression of the disease are likely to be different to those needed in young adult non-arthritic hips.
  • Similarly, the expectation of results following an arthroscopic procedure in an older adult with arthritis must also be different.
  • With an almost 5-fold increase in conversion rate from arthroscopy to arthroplasty in the over 50s population, arthroscopy in arthritis is a different procedure, with a different outcome, to arthroscopy in young adults with no evidence of osteoarthritis.
  • This article takes a closer inspection at outcomes following hip arthroscopy in the older population particularly in those with evidence of early arthritis.
  • This paper does not attempt to make recommendations in other diagnoses such as inflammatory arthritis or other secondary arthritides.
  • Although the nature of surgeons is to find new techniques and push boundaries, we highlight the need for caution in undertaking arthroscopic intervention when arthritis is already apparent at presentation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Br. 2009 Feb;91(2):162-9 [19190047.001]
  • [Cites] Clin Biomech (Bristol, Avon). 2016 Mar;33:13-9 [26895447.001]
  • [Cites] Arthroscopy. 2012 Jan;28(1):59-65 [21982390.001]
  • [Cites] Clin Orthop Relat Res. 2015 Mar;473(3):1055-73 [25231154.001]
  • [Cites] Int Orthop. 2011 Oct;35(10):1427-35 [21755334.001]
  • [Cites] Sports Med Arthrosc. 2015 Dec;23 (4):174-9 [26524551.001]
  • [Cites] Arthroscopy. 2015 Feb;31(2):231-8 [25442657.001]
  • [Cites] Arthroscopy. 2015 Mar;31(3):520-9 [25543247.001]
  • [Cites] Bone Joint J. 2013 Jan;95-B(1):10-9 [23307667.001]
  • [Cites] Clin Orthop Relat Res. 2009 Mar;467(3):747-52 [19089524.001]
  • [Cites] J Bone Joint Surg Br. 2011 Aug;93(8):1027-32 [21768624.001]
  • [Cites] J Bone Joint Surg Am. 2010 Oct 20;92(14):2436-44 [20962194.001]
  • [Cites] Br J Radiol. 1965 Nov;38(455):810-24 [5842578.001]
  • [Cites] Am J Sports Med. 2014 Dec;42(12 ):3009-15 [23966568.001]
  • [Cites] Clin Orthop Relat Res. 1986 Dec;(213):20-33 [3780093.001]
  • [Cites] Clin J Sport Med. 2014 Sep;24(5):435-7 [24346737.001]
  • [Cites] J Bone Joint Surg Br. 1961 Nov;43-B:752-7 [14038135.001]
  • [Cites] Arthroscopy. 2012 Oct;28(10):1359-64 [22906757.001]
  • [Cites] Acta Radiol. 2008 May;49(4):436-41 [18415788.001]
  • [Cites] Clin Orthop Relat Res. 2005 Dec;441:180-7 [16331001.001]
  • [Cites] Radiology. 2011 Aug;260(2):494-502 [21613440.001]
  • [Cites] Arthroscopy. 2014 Mar;30(3):305-10 [24468326.001]
  • [Cites] Osteoarthritis Cartilage. 2013 Oct;21(10 ):1514-21 [23850552.001]
  • [Cites] Clin Orthop Relat Res. 2001 Dec;(393):25-37 [11764355.001]
  • [Cites] PLoS One. 2015 Jan 30;10(1):e0113970 [25635392.001]
  • [Cites] Clin Orthop Relat Res. 2013 May;471(5):1639-45 [23179127.001]
  • [Cites] Am J Sports Med. 2010 Jun;38(6):1160-5 [20228244.001]
  • [Cites] Int Orthop. 2014 Aug;38(8):1615-20 [24687267.001]
  • [Cites] Arthroscopy. 2013 Nov;29(11):1777-82 [24209674.001]
  • [Cites] J Bone Joint Surg Am. 2011 Oct 5;93(19):e111(1-10) [22005872.001]
  • [Cites] Sports Med Arthrosc Rehabil Ther Technol. 2010 Jul 29;2:18 [20670440.001]
  • [Cites] Knee Surg Sports Traumatol Arthrosc. 2003 Nov;11(6):403-8 [12897984.001]
  • [Cites] J Bone Joint Surg Br. 2006 Dec;88(12):1557-66 [17159164.001]
  • [Cites] Arthroscopy. 2015 May;31(5):836-42 [25670336.001]
  • [Cites] Unfallchirurg. 2005 Jan;108(1):9-10, 12-7 [15619064.001]
  • [Cites] Clin Orthop Relat Res. 2003 Dec;(417):112-20 [14646708.001]
  • [Cites] Arthroscopy. 2012 Jun;28(6):743-4 [22632570.001]
  • [Cites] Clin Orthop Relat Res. 2013 Aug;471(8):2492-6 [23292888.001]
  • [Cites] Clin Orthop Relat Res. 2011 Feb;469(2):464-9 [20953854.001]
  • [Cites] Int Orthop. 2012 Jun;36(6):1115-21 [22371112.001]
  • (PMID = 28630715.001).
  • [ISSN] 2054-8397
  • [Journal-full-title] Journal of hip preservation surgery
  • [ISO-abbreviation] J Hip Preserv Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


3. Lee JI, Kim IH, Nam TJ: Crude extract and solvent fractions of Calystegia soldanella induce G1 and S phase arrest of the cell cycle in HepG2 cells. Int J Oncol; 2017 Feb;50(2):414-420
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This plant has long been used as an edible and medicinal herb to cure rheumatic arthritis, sore throat, dropsy, and scurvy.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Mol Cell Biol. 2012 Sep;13(9):579-90 [22914294.001]
  • [Cites] Nat Prod Commun. 2013 Apr;8(4):431-2 [23738443.001]
  • [Cites] J Nat Prod. 2011 Nov 28;74(11):2414-9 [21992192.001]
  • [Cites] J Pharm Bioallied Sci. 2016 Apr-Jun;8(2):83-91 [27134458.001]
  • [Cites] Mar Drugs. 2016 Feb 18;14 (2):null [26901207.001]
  • [Cites] Chem Pharm Bull (Tokyo). 2014;62(1):97-105 [24390499.001]
  • [Cites] Curr Med Chem. 2003 Dec;10(23):2549-58 [14529470.001]
  • [Cites] Eur J Cancer Prev. 2004 Oct;13(5):419-24 [15452455.001]
  • [Cites] Med Res Rev. 2016 Jan;36(1):169-89 [26332654.001]
  • [Cites] Mar Drugs. 2015 Sep 30;13(10):6152-209 [26437418.001]
  • [Cites] Food Chem Toxicol. 2010 Feb;48(2):722-8 [20026161.001]
  • [Cites] Nat Prod Res. 2013;27(21):1965-70 [23706100.001]
  • [Cites] Eur J Pharmacol. 2007 Dec 8;576(1-3):26-33 [17716651.001]
  • [Cites] PLoS One. 2016 Apr 11;11(4):e0151502 [27064569.001]
  • [Cites] Cytokine Growth Factor Rev. 2008 Jun-Aug;19(3-4):325-31 [18495520.001]
  • [Cites] Chem Pharm Bull (Tokyo). 2011;59(9):1163-8 [21881263.001]
  • [Cites] Nutr Cancer. 2013;65(2):255-62 [23441613.001]
  • [Cites] Bioorg Med Chem. 2015 Jun 15;23 (12 ):2810-8 [25703307.001]
  • [Cites] Nat Prod Bioprospect. 2014 Jun;4(3):189-96 [24955301.001]
  • [Cites] Nat Prod Commun. 2014 Nov;9(11):1585-8 [25532287.001]
  • [Cites] Chem Pharm Bull (Tokyo). 2014;62(8):839-44 [25087638.001]
  • [Cites] Phytochemistry. 2001 Jul;57(5):721-6 [11397439.001]
  • [Cites] FEBS Open Bio. 2016 Oct 24;6(11):1093-1101 [27833850.001]
  • [Cites] J Cancer Prev. 2015 Dec;20(4):241-9 [26734586.001]
  • [Cites] Bioorg Med Chem Lett. 2012 Jul 1;22(13):4318-22 [22652051.001]
  • [Cites] Asian Pac J Cancer Prev. 2012;13(12):6073-6 [23464406.001]
  • [Cites] Plant Cell Environ. 2002 Feb;25(2):275-294 [11841670.001]
  • [Cites] Yakugaku Zasshi. 1977 Dec;97(12):1369-71 [609052.001]
  • [Cites] CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29 [25559415.001]
  • [Cites] J Asian Nat Prod Res. 2014;16(4):370-5 [24597719.001]
  • [Cites] Cell Cycle. 2010 Feb 15;9(4):689-99 [20107323.001]
  • [Cites] Chem Pharm Bull (Tokyo). 2015;63(8):641-8 [26235171.001]
  • [Cites] Cancer Biol Ther. 2012 May;13(7):451-7 [22361734.001]
  • [Cites] Nat Prod Commun. 2014 Jul;9(7):921-4 [25230493.001]
  • [Cites] Nat Prod Res. 2014;28(13):960-6 [24945315.001]
  • [Cites] Fitoterapia. 2000 Aug;71(4):353-9 [10925003.001]
  • [Cites] Nat Prod Commun. 2011 Dec;6(12):1889-92 [22312731.001]
  • [Cites] Br J Pharmacol. 2014 Apr;171(7):1655-67 [24328908.001]
  • [Cites] Mar Drugs. 2014 Jul 07;12(7):4069-85 [25003791.001]
  • [Cites] C R Biol. 2008 Nov;331(11):865-73 [18940702.001]
  • [Cites] Chin Med J (Engl). 1999 Oct;112(10):887-91 [11717970.001]
  • [Cites] J Cell Biochem. 2008 May 1;104(1):339-56 [18092339.001]
  • (PMID = 28101580.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Plant Extracts
  •  go-up   go-down


Advertisement
4. Nguyen TD, Thuong PT, Hwang IH, Hoang TK, Nguyen MK, Nguyen HA, Na M: Anti-Hyperuricemic, Anti-Inflammatory and Analgesic Effects of Siegesbeckia orientalis L. Resulting from the Fraction with High Phenolic Content. BMC Complement Altern Med; 2017 Apr 04;17(1):191
Hazardous Substances Data Bank. CARRAGEENAN GUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-Hyperuricemic, Anti-Inflammatory and Analgesic Effects of Siegesbeckia orientalis L. Resulting from the Fraction with High Phenolic Content.
  • BACKGROUND: The medicinal plant Siegesbeckia orientalis L. has been commonly used for the treatment of acute arthritis, rheumatism, and gout in Vietnam.
  • Anti-hyperuricemic and anti-inflammatory effects were evaluated and observed for the crude ethanol extract (CEE) of S. orientalis.
  • Anti-inflammatory activities of the BuOH fr. were also evaluated in vivo using carrageenan-induced paw edema and urate-induced synovitis in rats.
  • CONCLUSIONS: This study suggested that anti-hyperuricemic and anti-inflammatory mechanism of S. orientalis is related to XO inhibitory effect of the phenolic components.
  • Our findings support the use of this plant as the treatment of gout and other inflammatory diseases.
  • [MeSH-major] Analgesics / therapeutic use. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Asteraceae / chemistry. Hyperuricemia / drug therapy. Phytotherapy. Plant Extracts / therapeutic use
  • [MeSH-minor] Animals. Carrageenan. Disease Models, Animal. Liver / drug effects. Liver / enzymology. Male. Phenols / chemistry. Phenols / isolation & purification. Plants, Medicinal. Rats. Rats, Wistar. Uric Acid / blood. Vietnam. Xanthine Oxidase / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1996 Feb 15;334(7):445-51 [8552148.001]
  • [Cites] Chem Pharm Bull (Tokyo). 2005 Feb;53(2):232-4 [15684525.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Jan;304(1):56-62 [12490575.001]
  • [Cites] J Ethnopharmacol. 2006 Dec 6;108(3):462-70 [16876348.001]
  • [Cites] Biol Pharm Bull. 2007 Aug;30(8):1551-6 [17666819.001]
  • [Cites] Acta Physiol Scand Suppl. 1986;554:221-33 [3469880.001]
  • [Cites] Pharmacol Res Commun. 1975 Apr;7(2):117-24 [1144488.001]
  • [Cites] Br J Pharmacol. 1997 Aug;121(8):1619-26 [9283695.001]
  • [Cites] Int J Food Sci Nutr. 2016;67(3):283-7 [26940252.001]
  • [Cites] Am J Manag Care. 2005 Nov;11(15 Suppl):S451-8; quiz S465-8 [16300459.001]
  • [Cites] J Ethnopharmacol. 2004 Jul;93(1):133-40 [15182918.001]
  • [Cites] Proc Soc Exp Biol Med. 1962 Dec;111:544-7 [14001233.001]
  • [Cites] N Engl J Med. 2011 Feb 3;364(5):443-52 [21288096.001]
  • [Cites] Food Chem Toxicol. 2011 Sep;49(9):1943-7 [21600261.001]
  • [Cites] J Nat Prod. 2009 Nov;72(11):2005-8 [19813758.001]
  • [Cites] J Nat Prod. 2014 Jul 25;77(7):1693-9 [25060641.001]
  • [Cites] J Nat Prod. 2004 Sep;67(9):1517-21 [15387652.001]
  • [Cites] Biomed Res Int. 2014;2014:329712 [25328884.001]
  • [Cites] Biol Pharm Bull. 2004 Sep;27(9):1414-21 [15340229.001]
  • [Cites] Free Radic Biol Med. 2014 Apr;69:300-7 [24503177.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Pain. 2000 Dec 15;89(1):65-74 [11113294.001]
  • [Cites] Arthritis Res Ther. 2010;12 (2):206 [20441605.001]
  • [Cites] Clin Chem. 1971 Mar;17(3):158-60 [5543187.001]
  • [Cites] Biol Pharm Bull. 2005 Dec;28(12):2231-4 [16327155.001]
  • [Cites] Phytomedicine. 2007 Dec;14(12):825-9 [17350237.001]
  • [Cites] J Ethnopharmacol. 2011 Oct 11;137(3):1089-94 [21798328.001]
  • [Cites] Pharmazie. 2014 Apr;69(4):243-56 [24791587.001]
  • (PMID = 28376775.001).
  • [ISSN] 1472-6882
  • [Journal-full-title] BMC complementary and alternative medicine
  • [ISO-abbreviation] BMC Complement Altern Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Analgesics; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Phenols; 0 / Plant Extracts; 268B43MJ25 / Uric Acid; 9000-07-1 / Carrageenan; EC 1.17.3.2 / Xanthine Oxidase
  • [Keywords] NOTNLM ; Analgesic activity / Anti-hyperuricemic activity / Anti-inflammatory activity / Caffeic acid analogues / Flavonones / Siegesbeckia orientalis / Xanthine oxidase
  •  go-up   go-down


5. Boeters DM, Mangnus L, Ajeganova S, Lindqvist E, Svensson B, Toes REM, Trouw LA, Huizinga TWJ, Berenbaum F, Morel J, Rantapää-Dahlqvist S, van der Helm-van Mil AHM: The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical. Arthritis Res Ther; 2017 May 31;19(1):115
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical.
  • BACKGROUND: Rheumatoid arthritis (RA) consists of two syndromes, one autoantibody-positive and one autoantibody-negative.
  • Further biologic studies are needed to characterize the pathogenesis of ACPA-negative polyarthritis at older age and to promote personalized treatment decisions in ACPA-negative patients in daily practice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Rheum Dis. 2016 Apr;76(4):716-720 [28283528.001]
  • [Cites] Ann Rheum Dis. 2006 Mar;65(3):366-71 [16014670.001]
  • [Cites] Rheumatology (Oxford). 2004 May;43(5):655-7 [14970400.001]
  • [Cites] Rheumatol Int. 2013 Nov;33(11):2881-4 [22955876.001]
  • [Cites] Arthritis Rheum. 2006 Dec;54(12):3799-808 [17133560.001]
  • [Cites] Joint Bone Spine. 2015 Jan;82(1):13-7 [25238951.001]
  • [Cites] Joint Bone Spine. 2016 Oct;83(5):511-5 [26992954.001]
  • [Cites] Ann Rheum Dis. 2011 Aug;70(8):1461-4 [21666230.001]
  • [Cites] Ann Rheum Dis. 2002 Dec;61(12):1055-9 [12429534.001]
  • [Cites] Ann Rheum Dis. 2011 Feb;70(2):259-65 [21156761.001]
  • [Cites] Semin Arthritis Rheum. 2012 Aug;42(1):23-31 [22465003.001]
  • [Cites] Ann Rheum Dis. 2017 Jan;76(1):112-118 [27117699.001]
  • [Cites] Rheumatol Int. 2003 Mar;23(2):70-4 [12634939.001]
  • [Cites] Arthritis Res Ther. 2015 Aug 24;17 :222 [26299443.001]
  • [Cites] Rheumatol Int. 2013 Apr;33(4):939-42 [22829412.001]
  • [Cites] Ann Rheum Dis. 2010 Jun;69(6):1110-6 [20439289.001]
  • [Cites] Ann Rheum Dis. 2011 Feb;70(2):373-9 [21068094.001]
  • [Cites] Arthritis Rheum. 1985 Sep;28(9):987-94 [4038365.001]
  • [Cites] BMC Med. 2013 Apr 04;11:94 [23556986.001]
  • [Cites] Arch Gerontol Geriatr. 2006 Mar-Apr;42(2):225-31 [16191448.001]
  • [Cites] J Rheumatol. 1997 Jan;24(1):20-7 [9002006.001]
  • [Cites] Ann Rheum Dis. 1959 Mar;18(1):49-51; French transl 51-2; Spanish transl 52-3 [13650459.001]
  • [Cites] Gerontology. 2009;55(3):250-8 [18849599.001]
  • [Cites] Rheumatology (Oxford). 2011 Jan;50(1):93-100 [20639266.001]
  • [Cites] Arthritis Res Ther. 2014 Apr 14;16(2):R94 [24731866.001]
  • [Cites] Ann Rheum Dis. 2017 Jan 2;:null [28043998.001]
  • [Cites] Vaccine. 2005 May 9;23(25):3232-5 [15837226.001]
  • [Cites] Rheum Dis Clin North Am. 2012 May;38(2):405-26 [22819092.001]
  • [Cites] Ann Rheum Dis. 2012 Oct;71(10 ):1651-7 [22440823.001]
  • [Cites] Arthritis Rheum. 1988 Mar;31(3):315-24 [3358796.001]
  • [Cites] Curr Opin Rheumatol. 2015 May;27(3):262-7 [25760280.001]
  • [Cites] Arthritis Rheum. 2006 Jan;54(1):38-46 [16385494.001]
  • [Cites] Vaccine. 2000 Feb 25;18(16):1624-8 [10689139.001]
  • [Cites] Arthritis Rheum. 2013 Jul;65(7):1684-93 [23529819.001]
  • [Cites] Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17372-7 [21987802.001]
  • [Cites] Clin Rheumatol. 2005 Sep;24(5):485-9 [15750680.001]
  • [Cites] Rheum Dis Clin North Am. 2000 Aug;26(3):517-26 [10989510.001]
  • [Cites] Rheumatology (Oxford). 2000 Sep;39(9):1031-6 [10986311.001]
  • [Cites] J Rheumatol. 2000 Jan;27(1):47-57 [10648017.001]
  • [Cites] Semin Arthritis Rheum. 1994 Jun;23(6):367-78 [7939723.001]
  • [Cites] Arthritis Care Res (Hoboken). 2014 Dec;66(12):1818-27 [24942650.001]
  • [Cites] Curr Aging Sci. 2015;8(2):131-46 [26212057.001]
  • [Cites] Curr Opin Rheumatol. 2014 Jan;26(1):93-100 [24296720.001]
  • (PMID = 28569212.001).
  • [ISSN] 1478-6362
  • [Journal-full-title] Arthritis research & therapy
  • [ISO-abbreviation] Arthritis Res. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; ACPA characteristics / Age / Autoantibodies / Rheumatoid arthritis
  •  go-up   go-down


6. Uroos M, Abbas Z, Sattar S, Umer N, Shabbir A, Shafiq-Ur-Rehman, Sharif A: &lt;i&gt;Nyctanthes arbor-tristis&lt;/i&gt; Ameliorated FCA-Induced Experimental Arthritis: A Comparative Study among Different Extracts. Evid Based Complement Alternat Med; 2017;2017:4634853

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] <i>Nyctanthes arbor-tristis</i> Ameliorated FCA-Induced Experimental Arthritis: A Comparative Study among Different Extracts.
  • <i>Nyctanthes arbor-tristis</i> (NAT) is commonly used traditionally for the treatment of rheumatism and inflammatory diseases.
  • NAT extracts suppressed arthritic scoring, paw edema, infiltration of inflammatory cells, pannus formation, and bone erosion.
  • Current study showed that <i>Nyctanthes arbor-tristis</i> ameliorated experimental rheumatoid arthritis and ethyl acetate extract possessed the highest inhibitory activity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Drug Discov. 2016 May;15(5):305-6 [27080040.001]
  • [Cites] F1000Prime Rep. 2014 May 06;6:31 [24860653.001]
  • [Cites] Basic Clin Pharmacol Toxicol. 2014 Sep;115(3):244-56 [25275147.001]
  • [Cites] Lancet. 2010 Sep 25;376(9746):1094-108 [20870100.001]
  • [Cites] J Postgrad Med. 2004 Jan-Mar;50(1):60-1 [15048003.001]
  • [Cites] Clin Med Insights Arthritis Musculoskelet Disord. 2013 Aug 08;6:35-43 [23997576.001]
  • [Cites] Int Immunopharmacol. 2015 May;26(1):265-71 [25863235.001]
  • [Cites] Evid Based Complement Alternat Med. 2011;2011:785245 [19770265.001]
  • [Cites] BMC Complement Altern Med. 2010 Oct 13;10:56 [20939932.001]
  • [Cites] Fundam Clin Pharmacol. 2014 Aug;28(4):455-64 [24102680.001]
  • [Cites] Inflammation. 2016 Dec;39(6):1918-1929 [27561645.001]
  • [Cites] Arthritis Res Ther. 2013;15 Suppl 3:S2 [24267197.001]
  • [Cites] J Ethnopharmacol. 2013 Apr 19;146(3):645-58 [23376280.001]
  • [Cites] Inflamm Allergy Drug Targets. 2009 Mar;8(1):28-39 [19275691.001]
  • [Cites] J Agric Food Chem. 2007 Oct 3;55(20):8040-6 [17867636.001]
  • [Cites] Eur J Pharmacol. 2014 Sep 5;738:263-72 [24943733.001]
  • [Cites] J Biol Chem. 2011 Sep 16;286(37):32866-74 [21799001.001]
  • [Cites] Nepal Med Coll J. 2011 Jun;13(2):74-6 [22364085.001]
  • [Cites] Evid Based Complement Alternat Med. 2014;2014:269431 [25614748.001]
  • [Cites] Front Immunol. 2015 Jul 27;6:384 [26284069.001]
  • [Cites] Biomed Res Int. 2015 ;2015 :786104 [26000303.001]
  • [Cites] Curr Med Chem. 2012;19(14):2104-27 [22414102.001]
  • [Cites] Evid Based Complement Alternat Med. 2011;2011:986797 [21234398.001]
  • [Cites] Biomed Res Int. 2013;2013:826295 [23984409.001]
  • [Cites] N Engl J Med. 2011 Dec 8;365(23):2205-19 [22150039.001]
  • [Cites] Arthritis Res Ther. 2009;11(3):229 [19519924.001]
  • [Cites] Evid Based Complement Alternat Med. 2016;2016:1230294 [27382402.001]
  • [Cites] Evid Based Complement Alternat Med. 2016;2016:8292486 [27525026.001]
  • (PMID = 28676830.001).
  • [ISSN] 1741-427X
  • [Journal-full-title] Evidence-based complementary and alternative medicine : eCAM
  • [ISO-abbreviation] Evid Based Complement Alternat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Chen ZZ, Zhang XD, Chen Y, Wu YB: The role of circulating miR-146a in patients with rheumatoid arthritis treated by Tripterygium wilfordii Hook F. Medicine (Baltimore); 2017 May;96(20):e6775
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of circulating miR-146a in patients with rheumatoid arthritis treated by Tripterygium wilfordii Hook F.
  • Rheumatoid arthritis (RA) is polygenic autoimmune disease with unclear etiology.
  • Expression of miR-146a was analyzed in RA patients (baseline, 12 weeks and 24 weeks) and HC.Circulating miR-146a expression was markedly increased in patients with RA compared with healthy controls (P < .001), ROC analysis of miR-146a for diagnosis for RA showed that the AUC was 0.908 (95% CI: 0.862-0.955) with a sensitivity of 87.0% and a specificity of 82.6% at best cutoff.
  • Moreover, miR-146a expression was markedly reduced after TwHF therapy (P < .001), and baseline miR-146a level was observed to present an increased tendency in responders compared with non-responders at 24 weeks (P = .066).Our study presented that circulating miR-146a level was correlated with risk and disease activity of RA patients by TwHF treatment, which could strikingly decrease expression of miR-146a in RA patients, and miR-146a may have a value in predicting clinical response of TwHF treatment.
  • [MeSH-major] Antirheumatic Agents / therapeutic use. Arthritis, Rheumatoid / blood. Arthritis, Rheumatoid / drug therapy. Drugs, Chinese Herbal / therapeutic use. MicroRNAs / blood. Phytotherapy. Tripterygium

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Res Ther. 2010;12(3):R81 [20459811.001]
  • [Cites] Rheumatol Int. 2014 May;34(5):659-64 [24610538.001]
  • [Cites] BioDrugs. 2012 Jun 1;26(3):131-41 [22494429.001]
  • [Cites] Med Res Rev. 2016 May;36(3):425-39 [26786912.001]
  • [Cites] Aging (Albany NY). 2009 Apr;1(4):402-11 [20148189.001]
  • [Cites] Oncotarget. 2016 Mar 22;7(12):13520-37 [26575329.001]
  • [Cites] Am J Transl Res. 2009 Mar 05;1(3):267-82 [19956437.001]
  • [Cites] J Rheumatol. 2015 Oct;42(10 ):1746-51 [26233505.001]
  • [Cites] Sci Rep. 2015 Apr 15;5:9700 [26814847.001]
  • [Cites] BMC Musculoskelet Disord. 2010 Sep 15;11:209 [20840794.001]
  • [Cites] Arthritis Res Ther. 2010;12(3):R86 [20470394.001]
  • [Cites] Arthritis Res Ther. 2008;10(4):R101 [18759964.001]
  • [Cites] Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii90-5 [23253933.001]
  • [Cites] Genet Test Mol Biomarkers. 2011 Nov;15(11):807-12 [21810022.001]
  • [Cites] Arthritis Rheum. 2008 May;58(5):1284-92 [18438844.001]
  • [Cites] Autoimmun Rev. 2015 Nov;14(11):1029-37 [26164649.001]
  • [Cites] Nat Immunol. 2005 Nov;6(11):1133-41 [16200068.001]
  • [Cites] Autoimmune Dis. 2014;2014:437231 [24688790.001]
  • [Cites] Pharmacoeconomics. 2014 Sep;32(9):841-51 [24859304.001]
  • [Cites] Nat Cell Biol. 2009 Sep;11(9):1143-9 [19684575.001]
  • [Cites] Arthritis Res Ther. 2015 Mar 09;17:49 [25860297.001]
  • [Cites] Ann Rheum Dis. 2015 Jun;74(6):1265-74 [24562503.001]
  • [Cites] J Cell Mol Med. 2014 Nov;18(11):2213-24 [25164131.001]
  • [Cites] J Autoimmun. 2009 May-Jun;32(3-4):189-94 [19303254.001]
  • (PMID = 28514293.001).
  • [ISSN] 1536-5964
  • [Journal-full-title] Medicine
  • [ISO-abbreviation] Medicine (Baltimore)
  • [Language] eng
  • [Publication-type] Journal Article; Observational Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antirheumatic Agents; 0 / Biomarkers; 0 / Drugs, Chinese Herbal; 0 / MIRN146 microRNA, human; 0 / MicroRNAs
  •  go-up   go-down


8. Albrecht K, Luque Ramos A, Callhoff J, Hoffmann F, Minden K, Zink A: [Outpatient care and disease burden of rheumatoid arthritis : Results of a linkage of claims data and a survey of insured persons]. Z Rheumatol; 2017 Mar 21;
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Outpatient care and disease burden of rheumatoid arthritis : Results of a linkage of claims data and a survey of insured persons].
  • [Transliterated title] Ambulante Versorgung und Krankheitslast der rheumatoiden Arthritis : Eine Analyse von Abrechnungsdaten und einer Versichertenbefragung.
  • BACKGROUND: Healthcare of patients with rheumatoid arthritis (RA) in Germany has mainly been evaluated in the past in RA cohorts from specialized arthritis centers.
  • A 31-item questionnaire covering patient reported diagnosis, healthcare utilization and burden of illness was sent to a stratified random sample of 6193 insured persons.
  • Data from the respondents regarding rheumatological care and disease status were evaluated.
  • RESULTS: In 2013 and 2014, a total of 96,921 adults with M05 or M06 diagnosis were insured.
  • The questionnaire was answered by 51% of the sample and of these 81% confirmed the RA diagnosis.
  • Treatment with disease-modifying antirheumatic drugs (DMARDs) was 61% (claims data) and 63% (respondents) in persons in rheumatological care but only 18% outside rheumatological care.
  • Patients with higher age and patients with M06 diagnosis had less drug prescriptions and were less frequently treated by rheumatologists.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28324149.001).
  • [ISSN] 1435-1250
  • [Journal-full-title] Zeitschrift fur Rheumatologie
  • [ISO-abbreviation] Z Rheumatol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Diagnostics / Disease burden / Drug treatment / Health care / Rheumatoid arthritis
  •  go-up   go-down


9. Patel K, Laloo D, Singh GK, Gadewar M, Patel DK: A review on medicinal uses, analytical techniques and pharmacological activities of Strychnos nux-vomica Linn.: A concise report. Chin J Integr Med; 2017 Jan 24;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Strychnos nux-vomica is an evergreen tree native to Southeast Asia and its dried seeds are used for the treatment of neurodisorders, arthritis and vomiting.
  • Pharmacologically it has been validated for its effect on inflammation, microbial infections, gastrointestinal problem, nervous system, bones cells, cardiovascular systems, cancer and blood glucose level.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28120207.001).
  • [ISSN] 1672-0415
  • [Journal-full-title] Chinese journal of integrative medicine
  • [ISO-abbreviation] Chin J Integr Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Keywords] NOTNLM ; Strychnos nux-vomica / analytical technique / herbal medicine / pharmacological activity / phytochemistry
  •  go-up   go-down


10. Williams K, Jacob AS, Levy SA: Investigation of the Anti-Inflammatory and Analgesic Effects of the Aqueous Extract Obtained from the Bark of Guiacum Officinale (Lignum Vitae). West Indian Med J; 2015 Nov 04;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of the Anti-Inflammatory and Analgesic Effects of the Aqueous Extract Obtained from the Bark of Guiacum Officinale (Lignum Vitae).
  • Background: The bark of <i>Guaiacum officinale</i> (lignum vitae) is used in folklore practice to relieve pain and swelling associated with arthritis and gout.
  • Significant anti-inflammatory effects were also observed with administration of 32 mg/kg lignum vitae extract.
  • Conclusion: The aqueous extract from lignum vitae bark showed significant anti-inflammatory and analgesic activity with no observable toxic effects at a dose ten times that of the other extract producing these pharmacological effects.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28103385.001).
  • [ISSN] 0043-3144
  • [Journal-full-title] The West Indian medical journal
  • [ISO-abbreviation] West Indian Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Jamaica
  •  go-up   go-down






Advertisement